Risk-factor clustering and cardiovascular disease risk in hypertensive patients

被引:62
作者
Weycker, Derek
Nichols, Gregory A.
O'Keeffe-Rosetti, Maureen
Edelsberg, John
Khan, Zeba M.
Kaura, Satyin
Oster, Gerry
机构
[1] Policy Anal Inc, Brookline, MA 02445 USA
[2] Kaiser Permanente Ctr Hlth Res, Portland, OR USA
[3] Novartis Pharma AG, Basel, Switzerland
关键词
hypertension; diabetes mellitus; dyslipidemias; obesity; metabolic syndrome; risk factors; cardiovascular diseases; costs; cost analysis; CORONARY-HEART-DISEASE; INSULIN-RESISTANCE SYNDROME; DIABETES-MELLITUS; MICROVASCULAR COMPLICATIONS; METABOLIC SYNDROME; BLOOD-PRESSURE; MORTALITY; MEN; ASSOCIATION; CHOLESTEROL;
D O I
10.1016/j.amjhyper.2006.10.013
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background: Patients with hypertension often have other major risk factors for cardiovascular disease (CVD). Little is known, however, about the extent of risk-factor clustering in these patients and its importance in CVD risk and medical-care costs. Methods: Study subjects were selected from the electronic medical records system of Kaiser Permanente Northwest, a large health maintenance organization, and included all patients aged >= 35 years with hypertension who were free of CVD in 1998. Subjects were stratified into eight risk-factor clusters based on whether or not they also had diabetes, hyperlipidemia, or a high body mass index (BMI). The risk of cardiovascular events was examined in each cluster over 6 years beginning January 1, 1999, using Kaplan-Meier methods and Cox proportional hazards models. Cumulative total medical-care costs (per patient) over 6 years also were examined. Results: A total of 57,573 patients with hypertension who were free of CVD in 1998 were identified; 56% ofsubjects also had diabetes, hyperlipidemia, or high BMI. In analyses controlling for age, sex, and smoking status, the relative risk of cardiovascular events over 6 years was highest for patients with comorbid diabetes, ranging from 2.07 (95% confidence interval, 1.86-2.30) for those with diabetes only to 2.80 (95% confidence interval, 2.48 -3.17) for those with diabetes, hyperlipidemia, and high BMI. Cumulative medical-care costs generally increased with additional risk factors. Comorbid diabetes had the greatest impact on costs over 6 years. Conclusions: More than 50% of patients with hypertension also had diabetes, hyperlipidemia, or high BMI. Patients with these additional risk factors (especially diabetes) had a substantially higher CVD risk and medical-care costs. Am J Hypertens 2007;20:599-607 (c) 2007 American Journal of Hypertension, Ltd.
引用
收藏
页码:599 / 607
页数:9
相关论文
共 32 条
[1]   Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study [J].
Adler, AI ;
Stratton, IM ;
Neil, HAW ;
Yudkin, JS ;
Matthews, DR ;
Cull, CA ;
Wright, AD ;
Turner, RC ;
Holman, RR .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :412-419
[2]   Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men - A general population study [J].
Adlerberth, AM ;
Rosengren, A ;
Wilhelmsen, L .
DIABETES CARE, 1998, 21 (04) :539-545
[3]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[4]  
2-S
[5]   Diabetes and cardiovascular events in hypertensive patients [J].
Alderman, MH ;
Cohen, H ;
Madhavan, S .
HYPERTENSION, 1999, 33 (05) :1130-1134
[6]  
ALLISON PD, 1995, SURVIVAL ANAL USING, P154
[7]  
Amer Diabet Assoc, 2005, DIABETES CARE, V28, pS37
[8]   The progressive cost of complications in type 2 diabetes mellitus [J].
Brown, JB ;
Pedula, KL ;
Bakst, AW .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (16) :1873-1880
[9]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[10]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696